Abeona Therapeutics Inc (NASDAQ:ABEO) Expected to Announce Earnings of -$0.17 Per Share

Analysts predict that Abeona Therapeutics Inc (NASDAQ:ABEO) will report earnings per share (EPS) of ($0.17) for the current quarter, Zacks Investment Research reports. Zero analysts have made estimates for Abeona Therapeutics’ earnings, with estimates ranging from ($0.17) to ($0.16). Abeona Therapeutics posted earnings of ($0.14) per share in the same quarter last year, which suggests a negative year over year growth rate of 21.4%. The business is expected to announce its next quarterly earnings results on Monday, August 9th.

On average, analysts expect that Abeona Therapeutics will report full year earnings of ($0.67) per share for the current financial year, with EPS estimates ranging from ($0.69) to ($0.66). For the next fiscal year, analysts anticipate that the company will report earnings of ($0.63) per share, with EPS estimates ranging from ($0.68) to ($0.55). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side research analysts that cover Abeona Therapeutics.

Abeona Therapeutics (NASDAQ:ABEO) last issued its quarterly earnings data on Tuesday, May 18th. The biopharmaceutical company reported ($0.17) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.19) by $0.02.

ABEO has been the subject of several analyst reports. Zacks Investment Research upgraded Abeona Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, May 21st. SVB Leerink restated a “buy” rating on shares of Abeona Therapeutics in a research note on Monday, March 29th. Finally, HC Wainwright restated a “buy” rating and set a $8.00 price target on shares of Abeona Therapeutics in a research note on Wednesday, April 14th. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company. Abeona Therapeutics has an average rating of “Buy” and a consensus target price of $4.40.

Shares of Abeona Therapeutics stock traded down $0.01 during trading hours on Tuesday, hitting $1.84. 2,147 shares of the company were exchanged, compared to its average volume of 3,076,083. Abeona Therapeutics has a 1 year low of $0.99 and a 1 year high of $3.79. The company has a quick ratio of 2.17, a current ratio of 2.17 and a debt-to-equity ratio of 0.01. The firm has a 50-day simple moving average of $1.61. The firm has a market capitalization of $182.19 million, a PE ratio of -3.30 and a beta of 1.43.

In related news, Director Sco Capital Partners Llc sold 80,000 shares of the company’s stock in a transaction on Thursday, March 18th. The stock was sold at an average price of $2.23, for a total transaction of $178,400.00. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, CAO Edward Carr sold 20,445 shares of the company’s stock in a transaction on Thursday, April 1st. The stock was sold at an average price of $1.85, for a total value of $37,823.25. Following the transaction, the chief accounting officer now directly owns 226,291 shares in the company, valued at approximately $418,638.35. The disclosure for this sale can be found here. Insiders have sold 180,854 shares of company stock worth $364,138 in the last ninety days. 15.40% of the stock is currently owned by corporate insiders.

Institutional investors have recently bought and sold shares of the business. Renaissance Technologies LLC grew its holdings in Abeona Therapeutics by 633.9% in the fourth quarter. Renaissance Technologies LLC now owns 1,322,903 shares of the biopharmaceutical company’s stock valued at $2,077,000 after purchasing an additional 1,142,652 shares during the last quarter. Virtu Financial LLC grew its holdings in Abeona Therapeutics by 217.0% in the fourth quarter. Virtu Financial LLC now owns 118,030 shares of the biopharmaceutical company’s stock valued at $185,000 after purchasing an additional 80,798 shares during the last quarter. Bank of New York Mellon Corp grew its holdings in Abeona Therapeutics by 7.6% in the fourth quarter. Bank of New York Mellon Corp now owns 280,733 shares of the biopharmaceutical company’s stock valued at $441,000 after purchasing an additional 19,947 shares during the last quarter. BlackRock Inc. grew its holdings in Abeona Therapeutics by 5.0% in the fourth quarter. BlackRock Inc. now owns 4,090,830 shares of the biopharmaceutical company’s stock valued at $6,423,000 after purchasing an additional 193,963 shares during the last quarter. Finally, Wells Fargo & Company MN grew its holdings in Abeona Therapeutics by 26.9% in the fourth quarter. Wells Fargo & Company MN now owns 80,942 shares of the biopharmaceutical company’s stock valued at $127,000 after purchasing an additional 17,168 shares during the last quarter. 31.60% of the stock is currently owned by institutional investors.

Abeona Therapeutics Company Profile

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.

Recommended Story: What are the qualifications of a portfolio manager?

Get a free copy of the Zacks research report on Abeona Therapeutics (ABEO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Abeona Therapeutics (NASDAQ:ABEO)

Receive News & Ratings for Abeona Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.